# BioDlink International Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biodlink-international-company

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.biodlink.com
- Total disclosed funding: $126M
- Latest round: Series B (Aug 8, 2018)
- Investors on record: 7

## About

Based in Suzhou, China and established in 2009, Based in China, BioDlink International Company Limited, formerly known as TOT BIOPHARM International Company Limited, is a pharmaceutical outsourcing company that focuses on the contract manufacturing of antibody-drug conjugates (ADCs). It has sub-branches offices in Beijing and Shanghai and has a production base in Suzhou.

In November 2019, the company was listed on the Hong Kong Stock Exchange under the ticker "1875". In January 2026, WuXi XDC offered to acquire at least 60% of the voting rights in BioDlink International Company Limited for approximately HKD 2.79 billion.

BioDlink International Company Limited offers CDMO (Contract Development and Manufacturing Organization) service, providing ADC (antibody-drug conjugate) integrated platform, protein/antibody platform, GMP (Good Manufacturing Practice) manufacturing and technology transfer.

## Funding rounds

- Series B, Aug 8, 2018, $102M — Chengwei Capital, Vivo Capital, Cathay Capital, China Universal Asset Management, Yuanta Financial Holdings, Center Laboratories, Inc.
- Series A, Feb 18, 2016, $24M — Chengwei Capital, Vivo Capital, Formosa Laboratories, Inc., Center Laboratories, Inc.

## Investors

- Chengwei Capital (https://capitalatlas.ai/funds/chengwei-capital) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- Formosa Laboratories, Inc. — Series A
- Center Laboratories, Inc. — Series A, Series B
- Cathay Capital — Series B
- China Universal Asset Management — Series B
- Yuanta Financial Holdings — Series B